Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous disease. At the 20th Congress of the European Hematology Association (EHA), Christian Gisselbrecht, MD, of Paris Diderot University, Paris, France, explains the clinical significance of molecularly subtyping DLBCL as germinal center B-cell (GCB) or non-GCB (activated B cell-like).
Get great new content delivered to your inboxSign up
By choosing to continue, you are confirming that you are a healthcare professional
Please enter your details if you would like to receive the latest Hemonc news and updates